27.71 USD
+0.21 (+0.76%)
27.71 USD
0 (0%)
LEGN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. The financial health of LEGN is average, but there are quite some concerns on its profitability. LEGN is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year LEGN has reported negative net income.
In the past year LEGN has reported a negative cash flow from operations.
In the past 5 years LEGN always reported negative net income.
LEGN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
LEGN has a Return On Assets of -14.01%. This is amongst the best in the industry. LEGN outperforms 81.43% of its industry peers.
LEGN has a better Return On Equity (-23.73%) than 81.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.01% | ||
| ROE | -23.73% | ||
| ROIC | N/A |
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of LEGN (60.55%) is better than 78.24% of its industry peers.
LEGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.55% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LEGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LEGN has been increased compared to 1 year ago.
LEGN has more shares outstanding than it did 5 years ago.
LEGN has a worse debt/assets ratio than last year.
2.2 Solvency
LEGN has an Altman-Z score of 5.87. This indicates that LEGN is financially healthy and has little risk of bankruptcy at the moment.
LEGN has a better Altman-Z score (5.87) than 75.98% of its industry peers.
LEGN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
LEGN's Debt to Equity ratio of 0.26 is on the low side compared to the rest of the industry. LEGN is outperformed by 67.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.87 |
ROIC/WACCN/A
WACC8.2%
2.3 Liquidity
A Current Ratio of 2.86 indicates that LEGN has no problem at all paying its short term obligations.
LEGN's Current ratio of 2.86 is on the low side compared to the rest of the industry. LEGN is outperformed by 64.73% of its industry peers.
A Quick Ratio of 2.80 indicates that LEGN has no problem at all paying its short term obligations.
With a Quick ratio value of 2.80, LEGN is not doing good in the industry: 63.79% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.86 | ||
| Quick Ratio | 2.8 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 32.11% over the past year.
The Revenue has grown by 74.74% in the past year. This is a very strong growth!
LEGN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 59.90% yearly.
EPS 1Y (TTM)32.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.65%
Revenue 1Y (TTM)74.74%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%69.99%
3.2 Future
Based on estimates for the next years, LEGN will show a very strong growth in Earnings Per Share. The EPS will grow by 38.16% on average per year.
Based on estimates for the next years, LEGN will show a very strong growth in Revenue. The Revenue will grow by 36.30% on average per year.
EPS Next Y-6.81%
EPS Next 2Y57.7%
EPS Next 3Y47.66%
EPS Next 5Y38.16%
Revenue Next Year67.55%
Revenue Next 2Y57.73%
Revenue Next 3Y50.16%
Revenue Next 5Y36.3%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LEGN. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 59.89 indicates a quite expensive valuation of LEGN.
Based on the Price/Forward Earnings ratio, LEGN is valued cheaper than 89.12% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.59, LEGN is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 59.89 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LEGN's earnings are expected to grow with 47.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.7%
EPS Next 3Y47.66%
5. Dividend
5.1 Amount
LEGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
27.71
+0.21 (+0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners47.54%
Inst Owner Change-0.95%
Ins Owners0.08%
Ins Owner ChangeN/A
Market Cap5.08B
Revenue(TTM)908.96M
Net Income(TTM)-239.99M
Analysts83.2
Price Target75.3 (171.74%)
Short Float %11.9%
Short Ratio7.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-233.4%
Min EPS beat(2)-351.12%
Max EPS beat(2)-115.69%
EPS beat(4)1
Avg EPS beat(4)-112.7%
Min EPS beat(4)-351.12%
Max EPS beat(4)143.99%
EPS beat(8)4
Avg EPS beat(8)-51.78%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.59%
Min Revenue beat(2)-2.02%
Max Revenue beat(2)9.2%
Revenue beat(4)2
Avg Revenue beat(4)2.04%
Min Revenue beat(4)-2.02%
Max Revenue beat(4)9.2%
Revenue beat(8)4
Avg Revenue beat(8)1.55%
Revenue beat(12)6
Avg Revenue beat(12)20.38%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.56%
PT rev (3m)-1.36%
EPS NQ rev (1m)-35.29%
EPS NQ rev (3m)-124.02%
EPS NY rev (1m)0%
EPS NY rev (3m)-15.76%
Revenue NQ rev (1m)2.23%
Revenue NQ rev (3m)-4.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 59.89 | ||
| P/S | 5.59 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.03 | ||
| P/tB | 5.03 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.29
EYN/A
EPS(NY)0.46
Fwd EY1.67%
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS4.95
BVpS5.51
TBVpS5.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.01% | ||
| ROE | -23.73% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.55% | ||
| FCFM | N/A |
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 78.25% | ||
| Cap/Sales | 2.01% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.86 | ||
| Quick Ratio | 2.8 | ||
| Altman-Z | 5.87 |
F-Score4
WACC8.2%
ROIC/WACCN/A
Cap/Depr(3y)97.56%
Cap/Depr(5y)226.91%
Cap/Sales(3y)9.76%
Cap/Sales(5y)32.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.65%
EPS Next Y-6.81%
EPS Next 2Y57.7%
EPS Next 3Y47.66%
EPS Next 5Y38.16%
Revenue 1Y (TTM)74.74%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%69.99%
Revenue Next Year67.55%
Revenue Next 2Y57.73%
Revenue Next 3Y50.16%
Revenue Next 5Y36.3%
EBIT growth 1Y45.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year65.66%
EBIT Next 3Y61.72%
EBIT Next 5Y35.95%
FCF growth 1Y61.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.38%
OCF growth 3YN/A
OCF growth 5YN/A
LEGEND BIOTECH CORP-ADR / LEGN FAQ
What is the ChartMill fundamental rating of LEGEND BIOTECH CORP-ADR (LEGN) stock?
ChartMill assigns a fundamental rating of 4 / 10 to LEGN.
What is the valuation status for LEGN stock?
ChartMill assigns a valuation rating of 2 / 10 to LEGEND BIOTECH CORP-ADR (LEGN). This can be considered as Overvalued.
Can you provide the profitability details for LEGEND BIOTECH CORP-ADR?
LEGEND BIOTECH CORP-ADR (LEGN) has a profitability rating of 2 / 10.
What is the expected EPS growth for LEGEND BIOTECH CORP-ADR (LEGN) stock?
The Earnings per Share (EPS) of LEGEND BIOTECH CORP-ADR (LEGN) is expected to decline by -6.81% in the next year.